Recently published in the new england journal of medicine detailing a new method of immunotherapy to slow down the progression of this cancer. This targeted therapy is based on the fact that pancreatic adenocarcinoma cells have a somatic mutation in the kras proto -oncogene (whose product is largely responsible for tumor formation). This makes them susceptible to uncontrolled division, and is also practically invisible to the immune system, specifically to cytotoxic t cells or cd8 + . In 2020, the researchers who developed the method took
a 71-year-old patient with progressive metastatic pancreatic adenocarcinoma who had already undergone other chemotherapy treatments without success. To fax number list carry out this technique, they extracted mononuclear cells from their peripheral blood, which they treated in vitro to produce their differentiation into t cells. Using genetic engineering techniques, these cells were reprogrammed so that the membrane receptor responsible for binding to hla (complex major histocompatibility) to specifically recognize the mutated kras protein of tumor cells.
Inesem business school course in antibiotic, immune and antineoplastic pharmacology more information the modified cells were selected by flow cytometry and transferred to the patient again. Similarly, immunotherapy was combined with chemotherapy treatments to increase the chances of success. Has pancreatic cancer fallen in combat? The results of the study are quite revealing, surprising and hopeful. The patient underwent follow-up by means of tomography of the status of her adenocarcinoma, revealing a palpable decrease in its size 85